Thrivent Financial for Lutherans
ATRA icon

Thrivent Financial for Lutherans’s Atara Biotherapeutics ATRA Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,946
Closed -$214K – 2467
2023
Q1 		$214K Hold
2,946
– – ﹤0.01% 2370
2022
Q4 		$241K Hold
2,946
– – ﹤0.01% 2304
2022
Q3 		$279K Hold
2,946
– – ﹤0.01% 2248
2022
Q2 		$573K Buy
+2,946
New +$481K ﹤0.01% 2026
2021
Q2 		– Sell
-1,785
Closed -$641K – 2455
2021
Q1 		$641K Sell
1,785
-1,850
-51% -$818K ﹤0.01% 2129
2020
Q4 		$1.78M Buy
3,635
+1,514
+71% +$699K ﹤0.01% 1389
2020
Q3 		$687K Sell
2,121
-17
-0.8% -$5.79K ﹤0.01% 1806
2020
Q2 		$779K Hold
2,138
– – ﹤0.01% 1666
2020
Q1 		$455K Buy
+2,138
New +$679K ﹤0.01% 1768

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Thrivent Financial for Lutherans's ATRA Position: Q2 2023 in Review

Thrivent Financial for Lutherans sold out of Atara Biotherapeutics (ATRA) in Q2 2023, closing a stake of 2,946 shares — an estimated $214K sold.

Thrivent Financial for Lutherans first reported a position in ATRA in Q1 2020 and held it in 9 quarters. The position peaked at $1.78M in Q4 2020. 118 funds tracked by Wall St. Rank hold ATRA as of Q2 2023.

  • Thrivent Financial for Lutherans reported no remaining Atara Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 2,946 Atara Biotherapeutics shares in Q2 2023, an estimated $214K.
  • Thrivent Financial for Lutherans first reported a position in Atara Biotherapeutics in Q1 2020 and held it in 9 quarters.
  • Thrivent Financial for Lutherans's Atara Biotherapeutics position peaked at $1.78M in Q4 2020.
  • 118 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.